骨髓干细胞治疗心脏疾病的临床新进展

摘要/Abstract

摘要： 骨髓干细胞为多潜能细胞,包括造血干细胞和间充质干细胞两类,以骨髓组织中含量最为丰富,具有自我更新及多向分化能力,在一定的条件下能被诱导分化为包括心肌细胞在内的多种细胞,可作为理想的种子细胞用于衰老和病变引起的组织器官损伤修复,尤其是应用于心肌梗死、缺血性心衰、难治性心绞痛、扩张型心肌病等心脏疾病的临床治疗。本文就临床骨髓干细胞治疗心脏病的研究报道做简要综述。

关键词: 骨髓干细胞, 心肌梗死, 缺血性心衰, 难治性心绞痛, 扩张型心肌病

Abstract: Bone marrow stem cells are a population of multipotent cells,including two types of hematopoietic stem cells and mesenchymal stem cells,which are widely exist in bone marrow tissue.With the capacity of self-renewal and multiple differentiation,under certain conditions,bone marrow stem cells can be induced to differentiate into a variety of cells including myocardial cells and be used as ideal seed cells for tissue and organ damage caused by aging and disease, especially for the clinical treatment of cardiovascular disease,such as myocardial infarction,ischemic heart failure,intractable angina,dilated cardiomyopathy and so on.The progress on the bone marrow stem cells for the treatment of cardiovascular disease were reviewed in this paper.

Key words: bone marrow stem cell, myocardial infarction, ischemic heart failure, intractable angina, dilated cardiomyopathy

中图分类号:

R541.4

赵春梅, 王安才, 王德国. 骨髓干细胞治疗心脏疾病的临床新进展[J]. 中国临床药理学与治疗学, 2014, 19(8): 948-952.

ZHAO Chun-mei, WANG An-cai, WANG De-guo. Progress on the treatment of cardiovascular disease with bone marrow stem cells[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(8): 948-952.

参考文献 27

[1]	Orlic D,Kajstura J,Chimenti S,et al.Bone marrow cells regenerate infarcted myocardium[J].Nature,2001,410:701-705.
[2]	Murry CE,Soonpaa MH,Reinecke H,et al.Haematopoietic stem cells do not transdifferentiate into cardiac myocytes in myocardial infarcts[J]. Nature, 2004,428:664-668.
[3]	Leistner DM, Fischer-Rasokat U,Honold J,et al.Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction (TOPCARE-AMI):Final 5-year results suggest long-term safety and efficacy[J].Clin Res Cardiol, 2011,100(10):925-934.
	Mansour S,Roy DC,Bouchard V,et al.One-Year Safety analysis of the compare-ami trial: comparison of intracoronary injection of cd133 bone marrow stem cells to placebo in patients after acute myocardial infarction and left ventricular dysfunction[J].Bone Marrow Res,2011,2011:385124.
[5]	Roncalli J,Mouquet F,Piot C,et al.Intracoronary autologous mononucleated bone marrow cell infusion for acute myocardial infarction:Results of the randomized multicenter BONAMI trial[J].Eur Heart J,2011,32(14):1748-1757.
[6]	Benedek I,Bucur O,Benedek T.Intracoronary infusion of mononuclear bone marrow-derived stem cells is associated with a lower plaque burden after four years[J].J Atheroscler Thromb, 2014,21(3):217-229.
[7]	Beitnes JO,Hopp E,Lunde K,et al.Long-term results after intracoronary injection of autologous mononuclear bone marrow cells in acute myocardial infarction:The ASTAMI randomised, controlled study[J].Heart,2009,95(24):1983-1989.
[8]	Beitnes JO,Gjesdal O,Lunde K,et al.Left ventricular systolic and diastolic function improve after acute myocardial infarction treated with acute percutaneous coronary intervention, but are not influenced by intracoronary injection of autologous mononuclear bone marrow cells:A 3 year serial echocardiographic sub-study of the randomized-controlled ASTAMI study[J].Eur J Echocardiogr,2011,12(2):98-106.
[9]	Rodrigo SF,Van Ramshorst J,Hoogslag GE,et al.Intramyocardial Injection of Autologous Bone Marrow-Derived Ex Vivo Expanded Mesenchymal Stem Cells in Acute Myocardial Infarction Patients is Feasible and Safe up to 5 Years of Follow-up[J].J Cardiovasc Transl Res,2013,6(5):816-825.
[10]	Gao LR,Pei XT,Ding QA,et al.A critical challenge: Dosage-related efficacy and acute complication intracoronary injection of autologous bone marrow mesenchymal stem cells in acute myocardial infarction[J].Int J Cardiol,2013,168(4):3191-3199.
[11]	Wöhrle J,Von Scheidt F,Schauwecker P,et al.Impact of cell number and microvascular obstruction in patients with bone-marrow derived cell therapy: final results from the randomized, double-blind, placebo controlled intracoronary Stem Cell therapy in patients with Acute Myocardial Infarction (SCAMI) trial[J].Clin Res Cardiol,2013,102(10):765-770.
[12]	Traverse JH,Henry TD,Ellis SG,et al.Effect of intracoronary delivery of autologous bone marrow mononuclear cells 2 to 3 weeks following acute myocardial infarction on left ventricular function:the LateTIME randomized trial[J].JAMA,2011,306(19):2110-2119.
[13]	Sürder D,Manka R,Lo Cicero V,et al.Intracoronary injection of bone marrow-derived mononuclear cells early or Late after acute myocardial infarction:effects on global left ventricular function[J].Circulation,2013,127(19):1968-1979.
[14]	Lu M,Liu S,Zheng Z,et al.A pilot trial of autologous bone marrow mononuclear cell transplantation through grafting artery: A sub-study focused on segmental left ventricular function recovery and scar reduction[J].Int J Cardiol,2013,168(3):2221-2227.
[15]	Ben-Mordechai T,Holbova R,Landa-Rouben N,et al.Macrophage Subpopulations are Essential for Infarct Repair with and without Stem Cell Therapy[J].J Am Coll Cardiol, 2013,62(20):1890-1901.
[16]	Duran JM,Makarewich CA,Sharp TE,et al.Bone-derived stem cells repair the heart after myocardial infarction through transdifferentiation and paracrine signaling mechanisms[J].Circ Res,2013,113(5):539-552.
[17]	Perin EC,Silva GV,Henry TD,et al.A randomized study of transendocardial injection of autologous bone marrow mononuclear cells and cell function analysis in ischemic heart failure (FOCUS-HF)[J].Am Heart J,2011,161(6):1078-1087.
[18]	Perin EC,Willerson JT,Pepine CJ,et al.Effect of transendocardial delivery of autologous bone marrow mononuclear cells on functional capacity, left ventricular function, and perfusion in chronic heart failure:the FOCUS-CCTRN trial[J].JAMA,2012,307(16):1717-1726.
[19]	Fisher SA,Dorée C,Brunskill SJ,et al.Bone Marrow Stem Cell Treatment for Ischemic Heart Disease in Patients with No Option of Revascularization: A Systematic Review and Meta-Analysis[J].PLoS One,2013,8(6):646-669.
[20]	de la Fuente LM,Stertzer SH,Argentieri J,et al.Transendocardial autologous bone marrow in chronic myocardial infarction using a helical needle catheter: 1-year follow-up in an open-label,nonrandomized,single-center pilot study (the TABMMI study)[J].Am Heart J,2007,154(79):71-77.
[21]	de la Fuente LM,Stertzer SH,Argentieri J,et al.Transendocardial autologous bone marrow in myocardial infarction induced heart failure, two-year follow-up in an open-label phase I safety study (the TABMMI study)[J].EuroIntervention,2011,7(7):805-812.
[22]	Hare JM,Fishman JE,Gerstenblith G,et al.Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy:the POSEIDON randomized trial[J].JAMA,2012,308(22):2369-2379.
[23]	Hu S, Liu S,Zheng Z,et al.Isolated coronary artery bypass graft combined with bone marrow mononuclear cells delivered through a graft vessel for patients with previous myocardial infarction and chronic heart failure:a single-center,randomized,double-blind,placebo-controlled clinical trial[J].J Am Coll Cardiol,2011,57(24):2409-2415.
[24]	Losordo DW,Schatz RA,White CJ,et al.Intramyocardial transplantation of autologous C<inline-formula><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="Mml1-1009-2501-19-8-948"><mml:msup><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">D</mml:mi></mml:mrow><mml:mrow><mml:mn>34</mml:mn></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mo>+</mml:mo></mml:mrow></mml:msup></mml:math></inline-formula> stem cells for intractable angina: a phase I/IIa double-blind, randomized controlled trial[J].Circulation,2007,115(25):3165-3172.
[25]	Losordo DW,Henry TD,Davidson C,et al.Intramyocardial autologous cd34+ cell therapy for refractory angina[J].Circ Res,2011,109(4):428-436.
[26]	Wang S,Cui J,Peng W,et al.Intracoronary autologous C<inline-formula><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="Mml2-1009-2501-19-8-948"><mml:msup><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">D</mml:mi></mml:mrow><mml:mrow><mml:mn>34</mml:mn></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mo>+</mml:mo></mml:mrow></mml:msup></mml:math></inline-formula> stem cell therapy for intractable angina[J].Cardiology,2010,117(2):140-147.
[27]	Seth S,Bhargava B,Narang R,et al.The ABCD(Autologous Bone marrow Cells in Dilated Cardiomyopathy) trial a long-term follow-up study[J].J Am Coll Cardiol, 2010,55(15):1643-1644.

[1]	郝潇, 赵美, 王文静, 张飞飞, 刘惠良, 党懿, 李树仁, 齐晓勇. 钠-葡萄糖共转运体2抑制剂在急性心肌梗死应用研究进展[J]. 中国临床药理学与治疗学, 2023, 28(7): 824-831.
[2]	钱锦, 王峰岩. 老年急性心肌梗死患者PCI术后血清NT-proBNP水平的影响因素并分析其对近期预后的影响[J]. 中国临床药理学与治疗学, 2023, 28(6): 658-665.
[3]	陈曦, 李拥军. 活血类中成药在心肌梗死后心脏修复中的作用[J]. 中国临床药理学与治疗学, 2022, 27(6): 680-688.
[4]	杨永康, 李静, 饶廷彩, 张骏艳. 金丝桃苷通过调节自噬水平减轻心肌梗死小鼠心脏及胸主动脉的损伤[J]. 中国临床药理学与治疗学, 2021, 26(6): 601-608.
[5]	赵玮, 吴悠扬, 林丛, 黄时伟, 陈皓, 姜文兵. 紫檀芪对急性心肌梗死大鼠心肌功能、心肌纤维化和炎症反应的作用及对Notch1/eIF3a信号通路的影响[J]. 中国临床药理学与治疗学, 2020, 25(5): 498-504.
[6]	傅小媚，霍然，邓赛，林潮金，范景皓，王萍，李松沛，秦爱萍，邹明辉，余细勇. 脂多糖刺激的骨髓间充质干细胞来源外泌体改善小鼠心肌梗死后炎症和纤维化[J]. 中国临床药理学与治疗学, 2019, 24(8): 841-851.
[7]	韦喻镪. 利拉鲁肽对急性心肌梗死PCI术后心肌的保护作用[J]. 中国临床药理学与治疗学, 2018, 23(2): 184-188.
[8]	浦春, 陶青松，朱翔，秦明明，武其文，冯钢. 三种心肌损伤标志物在急性心肌梗死早期诊断中的应用价值[J]. 中国临床药理学与治疗学, 2017, 22(1): 82-86.
[9]	邓祖跃. 虾青素对Beagle犬心肌梗死模型的保护作用及其降低氧化应激机制[J]. 中国临床药理学与治疗学, 2016, 21(5): 509-513.
[10]	何胜虎，周胜华，张晶,王雪飞,王大新. 急性ST段抬高型心肌梗死急诊PCI发生恶性心律失常临床特点及替罗非班的影响[J]. 中国临床药理学与治疗学, 2016, 21(4): 432-435.
[11]	蔚有权, 曹蘅. 重组人胰岛素样生长因子-Ι对心肌梗死大鼠心肌基质金属蛋白酶表达及心肌间质降解的影响[J]. 中国临床药理学与治疗学, 2014, 19(8): 866-871.
[12]	李益民, 黄进, 陆治平, 李翔宇, 何胜虎. 替罗非班对ST段抬高型急性心肌梗死患者血小板微粒的影响[J]. 中国临床药理学与治疗学, 2014, 19(12): 1403-1406.
[13]	周勇, 黄松群, 徐飞. 术前与术中使用替罗非班对急性ST段抬高心肌梗死急诊介入治疗慢血流的比较及安全性[J]. 中国临床药理学与治疗学, 2014, 19(11): 1268-1271.
[14]	李曙, 张根葆, 洪云, 陆晓华. 蝮蛇毒蛋白C激活物改善急性心肌梗死大鼠心功能的机制研究[J]. 中国临床药理学与治疗学, 2012, 17(2): 141-146.
[15]	朱刚艳, 徐红新, 田毅浩, 马红梅, 唐世琪, 汪福良, 邬松林. 曲美他嗪通过上调Bcl-2改善骨髓间质干细胞存活[J]. 中国临床药理学与治疗学, 2011, 16(7): 729-735.